Evaluation of the Pharmacokinetic Drug Interaction of Capmatinib With Itraconazole and Rifampicin and Potential Impact on Renal Transporters in Healthy Subjects-Reference-Cited by-同舟云学术

Evaluation of the Pharmacokinetic Drug Interaction of Capmatinib With Itraconazole and Rifampicin and Potential Impact on Renal Transporters in Healthy Subjects

Published:2022-11-02 Issue:2 Volume:63 Page:228-238
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharma

Author:

Cui Xiaoming¹,Chen Xinhui¹,Pognan Nathalie²,Sengupta Tirtha³,Rahmanzadeh Gholamreza⁴,Kornberger Ruediger⁵,Giovannini Monica⁶

Affiliation:

1. Novartis Institutes for BioMedical Research East Hanover New Jersey USA

2. Novartis Pharma S.A.S Rueil‐Malmaison France

3. Novartis Healthcare Pvt. Ltd. Hyderabad Telangana India

4. Novartis Pharma AG Basel Switzerland

5. Parexel International GmbH Early Phase Clinical Unit Berlin Germany

6. Global Drug Development Novartis Services Inc. East Hanover New Jersey USA

Funder

Novartis Pharmaceuticals Corporation

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.2153

Reference34 articles.

1. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention

2. A novel germ line juxtamembrane Met mutation in human gastric cancer

3. Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion;Lorenzato A;Cancer Res,2002

4. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable

5. MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non–Small Cell Lung Carcinoma with Poor Prognosis

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of the CYP3A inhibitors, voriconazole, itraconazole, and fluconazole on the pharmacokinetics of osimertinib in rats;PeerJ;2023-08-10